Center for International Health, University of Bergen, Bergen, Norway
Search for other papers by Kjersti S Bakken in
Google Scholar
PubMed
Department of Microbiology, Innlandet Hospital Trust, Lillehammer, Norway
Search for other papers by Kristina Randjelovic Nermo in
Google Scholar
PubMed
Department of Clinical Science, University of Bergen, Bergen, Norway
Search for other papers by Bjørn Gunnar Nedrebø in
Google Scholar
PubMed
Search for other papers by Tim I M Korevaar in
Google Scholar
PubMed
Department of Research, Innlandet Hospital Trust, Lillehammer, Norway
Search for other papers by Tor A Strand in
Google Scholar
PubMed
caused overdiagnosis of (subclinical) hypothyroidism and subsequent overtreatment ( 4 , 5 , 6 ). However, there is a lack of data that quantify this potential increase in thyroid hormone therapy from a national perspective. Interestingly, the diagnostic
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Search for other papers by Brendan J Nolan in
Google Scholar
PubMed
Search for other papers by Aviva S Frydman in
Google Scholar
PubMed
Search for other papers by Shalem Y Leemaqz in
Google Scholar
PubMed
Search for other papers by Meg Carroll in
Google Scholar
PubMed
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Search for other papers by Mathis Grossmann in
Google Scholar
PubMed
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Search for other papers by Jeffrey D Zajac in
Google Scholar
PubMed
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Search for other papers by Ada S Cheung in
Google Scholar
PubMed
Introduction Transgender (trans) individuals, including those who are binary and/or non-binary identified, undergoing feminising hormone therapy are often treated with oestradiol with or without anti-androgen therapy. Treatment allows the
Search for other papers by Lauren R Cirrincione in
Google Scholar
PubMed
Search for other papers by Bridgit O Crews in
Google Scholar
PubMed
Search for other papers by Jane A Dickerson in
Google Scholar
PubMed
Search for other papers by Matthew D Krasowski in
Google Scholar
PubMed
Search for other papers by Jessica Rongitsch in
Google Scholar
PubMed
Search for other papers by Katherine L Imborek in
Google Scholar
PubMed
CUNY Graduate School of Public Health and Health Policy, New York, New York, USA
Search for other papers by Zil Goldstein in
Google Scholar
PubMed
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA
Search for other papers by Dina N Greene in
Google Scholar
PubMed
Introduction Estradiol (17β-estradiol) is a natural sex steroid available in several exogenous preparations. The Endocrine Society recommended high-dose exogenous estradiol treatment as one part of feminizing hormone therapy for transgender
Search for other papers by Robert Rapaport in
Google Scholar
PubMed
Search for other papers by Peter A Lee in
Google Scholar
PubMed
Nemours/DuPont Hospital for Children, Wilmington, Delaware, USA
Search for other papers by Judith L Ross in
Google Scholar
PubMed
Search for other papers by Paul Saenger in
Google Scholar
PubMed
Search for other papers by Vlady Ostrow in
Google Scholar
PubMed
Search for other papers by Giuseppe Piccoli in
Google Scholar
PubMed
346 – 351 . ( https://doi.org/10.1007/BF03346369 ) 18475054 10.1007/BF03346369 9 Ross JL Lee PA Gut R Germak J. Increased height standard deviation scores in response to growth hormone therapy to near-adult height in older children with delayed
Search for other papers by María Dolores Rodríguez Arnao in
Google Scholar
PubMed
Search for other papers by Amparo Rodríguez Sánchez in
Google Scholar
PubMed
Search for other papers by Ignacio Díez López in
Google Scholar
PubMed
Search for other papers by Joaquín Ramírez Fernández in
Google Scholar
PubMed
Search for other papers by Jose Antonio Bermúdez de la Vega in
Google Scholar
PubMed
Search for other papers by Diego Yeste Fernández in
Google Scholar
PubMed
Search for other papers by María Chueca Guindulain in
Google Scholar
PubMed
Search for other papers by Raquel Corripio Collado in
Google Scholar
PubMed
Search for other papers by Jacobo Pérez Sánchez in
Google Scholar
PubMed
Search for other papers by Ana Fernández González in
Google Scholar
PubMed
Search for other papers by ECOS Spain Study Collaborative Investigator Group in
Google Scholar
PubMed
-2265.2009.03775.x ) 2 Richmond E Rogol AD . Current indications for growth hormone therapy for children and adolescents . Endocrine Development 2010 92 – 108 . ( https://doi.org/10.1159/000316130 ) 3 Loche S Carta L Ibba A Guzzetti C . Growth
Search for other papers by Urszula Smyczyńska in
Google Scholar
PubMed
Search for other papers by Joanna Smyczyńska in
Google Scholar
PubMed
Department of Paediatric Endocrinology, Medical University of Lodz, Lodz, Poland
Search for other papers by Maciej Hilczer in
Google Scholar
PubMed
Search for other papers by Renata Stawerska in
Google Scholar
PubMed
Search for other papers by Ryszard Tadeusiewicz in
Google Scholar
PubMed
Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland
Search for other papers by Andrzej Lewiński in
Google Scholar
PubMed
.1203/00006450-200010000-00010 11004238 10 Salah N Abd El Dayem SM El Mogy F Amin M Ibrahim M . Egyptian growth hormone deficient patients: demographic, auxological characterization and response to growth hormone therapy . Journal of Pediatric Endocrinology and Metabolism 2013 26
Search for other papers by Patrizia Bruzzi in
Google Scholar
PubMed
Search for other papers by Silvia Vannelli in
Google Scholar
PubMed
Search for other papers by Emanuela Scarano in
Google Scholar
PubMed
Search for other papers by Natascia Di Iorgi in
Google Scholar
PubMed
Search for other papers by Maria Parpagnoli in
Google Scholar
PubMed
Search for other papers by MariaCarolina Salerno in
Google Scholar
PubMed
Search for other papers by Marco Pitea in
Google Scholar
PubMed
Search for other papers by Maria Elisabeth Street in
Google Scholar
PubMed
Search for other papers by Andrea Secco in
Google Scholar
PubMed
Search for other papers by Adolfo Andrea Trettene in
Google Scholar
PubMed
Search for other papers by Malgorzata Wasniewska in
Google Scholar
PubMed
Search for other papers by Nicola Corciulo in
Google Scholar
PubMed
Search for other papers by Gianluca Tornese in
Google Scholar
PubMed
Search for other papers by Maria Felicia Faienza in
Google Scholar
PubMed
Search for other papers by Maurizio Delvecchio in
Google Scholar
PubMed
Search for other papers by Simona Filomena Madeo in
Google Scholar
PubMed
Search for other papers by Lorenzo Iughetti in
Google Scholar
PubMed
Savage MO . The changing face of paediatric human growth hormone therapy . Endocrines 3 419 – 427 . ( https://doi.org/10.3390/endocrines3030033 ) 10 Blum WF Ross JL Zimmermann AG Quigley CA Child CJ Kalifa G Deal C Drop SLS Rappold
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Mette Bøgehave in
Google Scholar
PubMed
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
OPEN, Open Patient data Explorative Network, Odense University Hospital, Region of Southern Denmark, Odense, Denmark
Search for other papers by Dorte Glintborg in
Google Scholar
PubMed
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Jørgen Brodersen Gram in
Google Scholar
PubMed
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Else-Marie Bladbjerg in
Google Scholar
PubMed
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Marianne Skovsager Andersen in
Google Scholar
PubMed
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Johannes Jakobsen Sidelmann in
Google Scholar
PubMed
Introduction
Hypogonadism is prevalent during opioid treatment, and low testosterone concentrations are associated with cardiovascular disease. The effect of testosterone replacement therapy (TRT) on the coagulation system in men with hypogonadism is not clarified. We investigate the effects of TRT on the tissue factor (TF) and contact activation pathways of coagulation in opioid-treated men.
Materials and methods
This was a double-blinded, placebo-controlled study in 37 men with total testosterone < 12 nmol/L randomized to 24 weeks of testosterone injections (n = 17) or placebo (n = 20). Variables of the coagulation system were analysed at baseline and after 24 weeks. Measurements included the TF pathway (endogenous thrombin potential (ETP) and peak thrombin), the contact activation pathway (endogenous kallikrein potential (EKP) and peak kallikrein), coagulation factors (FVII, FX, prothrombin, and FXII), and inhibitors (tissue factor pathway inhibitor (TFPI), protein C, protein S, antithrombin, and C1 esterase inhibitor (C1inh)). Between-group differences at 24 weeks were determined with analysis of covariance. Within-group changes in TRT and placebo were analysed with paired t-test.
Results
Between-group differences at 24 weeks were observed for ETP (P = 0.036), FVII (P = 0.044), FX (P = 0.015), prothrombin (P = 0.003), protein C (P = 0.004), and protein S (P = 0.038). Within the TRT group, ETP, peak thrombin, FVII, FX, prothrombin, TFPI, protein C, FXII, and C1inh decreased and protein S increased (all P < 0.05). Within the placebo group, coagulation outcomes were unchanged.
Conclusion
TRT affects the coagulation system in an anticoagulant direction through suppressed TF pathway in men with opioid-induced hypogonadism.
Search for other papers by Guido Zavatta in
Google Scholar
PubMed
Search for other papers by Bart L Clarke in
Google Scholar
PubMed
-term data on the impact of hormone therapy on chronic complications has limited use of rhPTH(1–84) as a new therapeutic option. In addition, the FDA withdrawal of rhPTH(1–84) from the market on September 5, 2019, has limited use of intact PTH in the USA over
Search for other papers by Lachlan Angus in
Google Scholar
PubMed
Search for other papers by Shalem Leemaqz in
Google Scholar
PubMed
Search for other papers by Olivia Ooi in
Google Scholar
PubMed
Search for other papers by Pauline Cundill in
Google Scholar
PubMed
Search for other papers by Nicholas Silberstein in
Google Scholar
PubMed
Search for other papers by Peter Locke in
Google Scholar
PubMed
Search for other papers by Jeffrey D Zajac in
Google Scholar
PubMed
Search for other papers by Ada S Cheung in
Google Scholar
PubMed
oestradiol as feminising gender-affirming hormone therapy ( 3 ). Goals of therapy are generally to increase serum oestradiol concentrations and lower serum total testosterone concentrations to achieve sex steroid concentrations in the female reference range